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Welcome to this special issue of PPAR research, PPARs,
and anticancer therapies. Peroxisomal proliferator-activated
receptor (PPAR) α, δ,a n dγ are members of the nuclear
hormone receptor superfamily of ligand-activated transcrip-
tion factors ﬁrst identiﬁed some 20 years ago. Although
initial studies focused on their role in regulating cellular
metabolism, there has been an increasing appreciation for
PPARs’ role in regulating a wide variety of biological
processes,particularlyinﬂammationandcancer.Modulation
of these processes is of particular importance with regard to
increasing the therapeutic outcome for cancer patients. This
special issue brings together reviews and research articles
that focus on the role of PPARs with respect to prognostic
outcome, anticancer activity, and normal tissue morbidity,
thus demonstrating the exciting therapeutic opportunities
that are within our grasp.
The ability of PPARs to promote or inhibit cancer has
been discussed for some time. In this special issue of PPAR
research, the ﬁrst section contains two research articles that
focusontheroleofPPARγ inmalignantmelanoma.Amech-
anistic study described by Klopper and colleagues illustrates
how the response of poorly diﬀerentiated melanoma cells to
PPARγ and retinoid X receptor agonists is mediated through
the calcium binding protein S100A2. The necessary presence
of S100A2 for the maximum antiproliferative eﬀectofPPARs
indicates a potential mechanism of tumor response or
resistance to PPARγ-directed anticancer therapy. Additional
support for a therapeutic role for PPARγ comes from
tissue microarray analyses of normal and tumor tissue from
patients with malignant melanoma described by Meyer and
colleagues. They report that PPARγ and cyclooxygenase 2
(Cox2)arestage-dependentprognosticmarkersofmalignant
melanoma. Moreover, in metastatic malignant melanoma,
PPARγ expression may predict for response to bimodulatory
stroma-targeted therapy combining Cox/PPAR targeting
with metronomic, low-dose chemotherapy. In addition, this
article opens the concept of the stroma-tumor interaction
complexity.
These research articles are followed by ﬁve reviews that
demonstrate the potential ability of PPARs to increase the
therapeutic window for cancer patients. All of these items
strengthen the growing evidence that PPARs’ ligands serve as
coadjuvants in protection of healthy tissue and in enhancing
anticancer therapies. With ongoing improvements in cancer
therapy and health care, the population of long-term cancer
survivors continues to grow. In the US approximately 62%
of adult and over 75% of pediatric cancer patients survive
beyond 5years. For this growing population, late eﬀects of
anticancer therapies pose a signiﬁcant risk and can adversely
aﬀect the quality of life of these individuals. Ramanan
et al. discuss the growing problem of radiation-induced
brain injury, particularly cognitive impairment, observed
in patients who survive 6months or more after partial or
whole-brain irradiation (WBI) for primary or metastatic
brain cancer. Recent studies suggest that the pathogenesis
of radiation-induced brain injury involves WBI-mediated
increases in oxidative stress and/or inﬂammatory responses
in the brain. PPAR agonists can cross the blood brain barrier,
have well-described anti-inﬂammatory and neuroprotective
properties, and as reported in this review do appear to2 PPAR Research
modulate late radiation-induced brain injury, including
cognitive impairment, in rodent models.
PPAR-mediated modulation of radiation-induced gas-
trointestinal toxicity is similarly reviewed by Linard and
Souidi. Radiation-induced gastrointestinal morbidity for the
treatment of pelvic and abdominal tumors is more common
than generally recognized and can negatively impact the
patient’s quality of life. Although the role of PPARγ in colon
cancer has been investigated for several years, relatively little
is known regarding its potential to protect the gut against
radiation-induced injury. This review discusses the eﬀects of
abdominal radiation on PPARs, their role and function in
radiation-induced toxicity, and the possibility of using PPAR
agonists as radioprotectors.
Translating these ﬁndings to the clinic is predicated by
demonstrating that PPAR agonists will not similarly protect
cancer cells. The therapeutic implications of using PPAR
agonists in the treatment of human neuroepithelial tumors,
including astrocytomas, the highly aggressive glioblastoma
multiforme, and pediatric neuroblastomas, are reviewed
by Benedetti and colleagues. The majority of malignant
neuroepithelial tumors have poor prognosis, and despite
multimodality therapy consisting of surgery, radiation ther-
apy, and chemotherapy, long-term survival rates remain
poor. These tumor cells express PPARs; thus natural and
synthetic PPAR ligands may represent promising adjuvant
therapeutic agents when used with existing anticancer
therapies. Simpson-Haidaris and colleagues highlight the
potential uses for PPARγ agonists in anticancer therapy,
with special emphasis on their role as an adjuvant or
in combined therapy in the treatment of hematological
malignancies found in the vasculature, marrow, and eyes. In
addition, they review that the potential roles of PPARγ and
its ligands may play in modulating cancer-associated angio-
genesis and tumor-stromal microenvironment crosstalk in
the bone marrow. Finally, Wagner and colleagues review
how PPAR agonists and retinoids can inhibit osteosarcoma
proliferation, induce apoptosis, and inhibit tumor growth
by promoting osteoblastic terminal diﬀerentiation. PPAR
agonists have the potential to be used not only as adjuvant
therapeutic drugs for osteosarcoma but also as chemopre-
ventive agents for those patients who undergo resection of
primary bone tumors in order to prevent local recurrence
and/or pulmonary metastasis.
In conclusion, we hope that you will ﬁnd these recent
advances in the potential role that PPARs and their agonists
play in anticancer therapies both informative and exciting.
We thank many authors who have contributed to the articles
in this special issue and encourage you to further stimulate
yourresearchintotheroleofPPARsandcancer.Themillions
of individuals who are impacted either directly or indirectly
by cancer deserve no less.
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